FDA Proposes Hub-and-Spoke Drug Registration Change; Comments Due Sept. 11

FDA issued a proposed rule that would modernize how drug manufacturers register and list products—especially for “hub-and-spoke” distributed manufacturing networks. Under the proposal, qualifying networks could register as a single establishment and use an expedited approach to update FDA records when units are added, removed, or (in some cases) mobile units are relocated. FDA also proposes clarifications for certain foreign drug establishments tied to importation or being offered for import into the United States. The public comment deadline is September 11, 2026.

Why FDA is revisiting drug establishment registration

Drug supply chains increasingly rely on distributed manufacturing, where different parts of production occur across multiple locations rather than one continuous site. FDA says registration and listing rules need to better match these operational realities so the agency can maintain visibility into upstream supply-chain risk and respond more effectively during drug-supply problems.

What the proposed rule would change

The proposal focuses on two parts of FDA’s compliance framework: drug establishment registration and drug listing.

• Hub-and-spoke networks could register as one establishment. Instead of requiring separate registration for each unit location within a qualifying distributed manufacturing network, FDA proposes allowing the network to register as a single establishment.
• Expedited updates for operational changes. FDA proposes an approach intended to streamline updates when network units are added or removed, or when mobile units are relocated—helping keep FDA’s information current without repeating the full registration process each time the network changes.
• Foreign establishment registration/listing clarifications tied to import. FDA proposes updates explaining how certain foreign drug establishments are expected to register and list when products are imported into the U.S. or offered for import.

Who is affected (and what to watch next)

The proposal primarily affects drug manufacturers and compliance/quality teams that manage distributed manufacturing networks—especially networks operating with a hub-and-spoke structure. If finalized, it could change how a network is represented to FDA for registration and listing, and how teams handle updates when units shift over time.

Because this is a proposed rule, key details—such as eligibility and how the expedited update process works in practice—could change before FDA issues a final rule. The most immediate public checkpoint is whether FDA receives substantive comments that push for scope changes, clearer definitions, or different update mechanics.

Key timeline: when the public can weigh in

FDA announced the proposed rule on July 10, 2026, and it was published in the Federal Register on July 13, 2026. Comments are due September 11, 2026.

Bottom line

FDA’s proposal aims to bring registration and listing rules in line with distributed manufacturing practices—while improving FDA’s ability to monitor supply-chain risk. For industry and compliance teams, the near-term decision point is the September 11, 2026 comment deadline; for everyone else, the longer-term watch is whether the final rule narrows or expands the hub-and-spoke and foreign-import scope.

Sources

• FDA press announcement (July 10, 2026): proposed rule overview
• Federal Register proposed rule (July 13, 2026; docket 2026-14073): requirements + comment deadline
• GovInfo PDF: Federal Register proposed rule text (2026-14073)